Sorry, you need to enable JavaScript to visit this website.
Microencapsulated benzoyl peroxide highlighted on a finger for the EPSOLAY cream campaign

Clearer skin in as early as 2 weeks1,2

Rosacea relief you can see3

EPSOLAY cream was studied in 2 clinical trials that analyzed the results of 733 people (18 or older) with moderate to severe papulopustular rosacea over 12 weeks.3 Check out the photos below to see some of the results from the study.

Patient 1, baseline and week 2 Patient 1, baseline and week 2 Patient 1, baseline and week 2
  • Patient 1, baseline and week 2
  • Patient 1, baseline and week 4
  • Patient 1, baseline and week 8
  • Patient 1, baseline and week 12
  • Patient 2, baseline and week 2
  • Patient 2, baseline and week 4
  • Patient 2, baseline and week 8
  • Patient 2, baseline and week 12
  • Patient 3, baseline and week 2
  • Patient 3, baseline and week 4
  • Patient 3, baseline and week 8
  • Patient 3, baseline and week 12
  • Age: 54

    Female

  • Age: 49

    Male

  • Age: 36

    Female

The most common adverse reactions (incidence ≥1%) in patients treated with EPSOLAY cream were pain, erythema (redness), pruritus (itching), and edema (swelling), all at the application site.3

Face of a woman with rosacea in her mid-50s grinning with left hand on cheek
Designed to be part of your daily routine3

EPSOLAY cream is made to use every day or as prescribed.

Once you start using EPSOLAY cream, it's important to stick to your routine to give yourself the best chance of seeing clearer skin.

HOW TO APPLY

Support at every step. Get updates straight to your inbox.

Stay Connected

References: 1. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-54-01; January 8, 2020. 2. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-54-02; March 26, 2020. 3. EPSOLAY (benzoyl peroxide) cream, 5% [Prescribing Information]. Whippany, NJ: Sol-Gel Technologies Ltd.; April 2021.

IMPORTANT SAFETY INFORMATION

Indication: EPSOLAY® (benzoyl peroxide) Cream, 5% is indicated for the treatment of inflammatory lesions of rosacea in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with EPSOLAY Cream were pain, erythema (redness), pruritus (itching) and edema (swelling), all at the application site. Warnings/Precautions: Patients using EPSOLAY Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of EPSOLAY Cream immediately and seek medical attention/initiate appropriate therapy. Skin Irritation/contact dermatitis may be experienced, including erythema (redness), scaling, dryness, and stinging/burning. Irritation and contact dermatitis may occur. Use a moisturizer and discontinue EPSOLAY Cream if symptoms do not improve. Avoid application to cuts, abrasions, eczematous, or sunburned skin. EPSOLAY Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of EPSOLAY Cream at the first evidence of sunburn.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

IMPORTANT SAFETY INFORMATION

Indication: EPSOLAY® (benzoyl peroxide) Cream, 5% is indicated for the treatment of inflammatory lesions of rosacea in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with EPSOLAY Cream were pain, erythema (redness), pruritus (itching) and edema (swelling), all at the application site. Warnings/Precautions: Patients using EPSOLAY Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of EPSOLAY Cream immediately and seek medical attention/initiate appropriate therapy. Skin Irritation/contact dermatitis may be experienced, including erythema (redness), scaling, dryness, and stinging/burning. Irritation and contact dermatitis may occur. Use a moisturizer and discontinue EPSOLAY Cream if symptoms do not improve. Avoid application to cuts, abrasions, eczematous, or sunburned skin. EPSOLAY Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of EPSOLAY Cream at the first evidence of sunburn.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Stay connected

Sign up for updates about EPSOLAY cream and additional information about rosacea.

Please enter first name
Please enter last name
Please enter email
Please enter ZIP code
Please enter phone
Please choose
Please agree to the Terms of Use and Privacy Policy
By completing and submitting this form, you grant permission and agree to allow Galderma Laboratories, L.P., and its affiliates (“Galderma”) to collect the information you provide so that Galderma may market or advertise to you across multiple channels regarding EPSOLAY cream. Galderma will not sell or share this information with third parties. For additional information regarding how Galderma handles your information, please see our privacy policy. *Required. *Please enter the fields above.

Thank you for your interest in staying up to date on EPSOLAY cream.

Sign up for updates about EPSOLAY cream and additional information about rosacea.

HOME

Are you a healthcare professional?

The information contained in this section of the website is intended for US healthcare professionals only.